Evidence map›Paper›PMID 26209266›Full record

ArticleBioorganic & medicinal chemistry2015

Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.

Son T Nguyen, Steven M Kwasny, Xiaoyuan Ding, John D Williams, Norton P Peet, Terry L Bowlin, Timothy J Opperman

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Son T NguyenMicrobiotix, Inc., One Innovation Dr., Worcester, MA 01605, United States.
Steven M KwasnyMicrobiotix, Inc., One Innovation Dr., Worcester, MA 01605, United States.
Xiaoyuan DingMicrobiotix, Inc., One Innovation Dr., Worcester, MA 01605, United States.
John D WilliamsMicrobiotix, Inc., One Innovation Dr., Worcester, MA 01605, United States.
Norton P PeetMicrobiotix, Inc., One Innovation Dr., Worcester, MA 01605, United States.
Terry L BowlinMicrobiotix, Inc., One Innovation Dr., Worcester, MA 01605, United States.
Timothy J OppermanMicrobiotix, Inc., One Innovation Dr., Worcester, MA 01605, United States. Electronic address: topperman@microbiotix.com.
Microbiotix (United States) · US

Funding

Development of a Novel Lead Series Against Category A & B Bacterial PathogensU01AI082052 · NIAID · MICROBIOTIX, INC · PI BOWLIN, TERRY L. · 2009 to 2013
$5.7M
Novel Antibacterials Targeting Gram-negative NonfermentersR43AI083032 · NIAID · MICROBIOTIX, INC · PI BUTLER, MICHELLE M. · 2009 to 2010
$521k
NIAID NIH HHS 1R43 AI083032NIAID NIH HHS 5 U01 AI 082052-03NIAID NIH HHS R43 AI083032NIAID NIH HHS U01 AI082052
6 · The paper itself

Abstract

Herein, we describe the antifungal evaluation of 43 bisamidine compounds, of which 26 are new, having the scaffold [Am]-[HetAr]-[linker]-[HetAr]-[Am], in which [Am] is a cyclic or acyclic amidine group, [linker] is a benzene, pyridine, pyrimidine, pyrazine ring, or an aliphatic chain of two to four carbon, and [HetAr] is a 5,6-bicyclic heterocycle such as indole, benzimidazole, imidazopyridine, benzofuran, or benzothiophene. In the head-to-head series the two [HetAr] units are oriented such that the 5-membered rings are connected through the linker, and in the head-to-tail series, one of the [HetAr] systems is connected through the 6-membered ring; additionally, in some of the head-to-tail compounds, the [linker] is omitted. Many of these compounds exhibited significant antifungal activity against Candida albicans, Candida krusei, Candida glabrata, Candida parapsilosis, and Cryptococcus neoformans (MIC ⩽ 4 μg/ml). The most potent compounds, for example, P10, P19 and P34, are comparable in antifungal activities to amphotericin B (MIC 0.125 μg/ml). They exhibited rapid fungicidal activity (>3 log10 decrease in cfu/ml in 4h) at concentrations equivalent to 4× the MIC in time kill experiments. The bisamidines strongly inhibited DNA, RNA and cell wall biosynthesis in C. albicans in macromolecular synthesis assays. However, the half-maximal inhibitory concentration for DNA synthesis was approximately 30-fold lower than those for RNA and cell wall biosynthesis. Fluorescence microscopy of intact cells of C. albicans treated with a bisamidine exhibited enhanced fluorescence in the presence of DNA, demonstrating that the bisamidine was localized to the nucleus. The results of this study show that bisamidines are potent antifungal agents with rapid fungicidal activity, which is likely to be the result of their DNA-binding activity. Although it was difficult to obtain a broad-spectrum antifungal compound with low cytotoxicity, some of the compounds (e.g., P9, P14 and P43) exhibited favorable CC50 values against HeLa cells and maintained considerable antifungal activity.

Indexed as

Antifungal AgentsCandidaCryptococcus neoformansDNA-Binding ProteinsFuransHumansAntifungal AgentsbisamidineDNA-Binding ProteinsFuransAntifungalBisamidinesCandidaCryptococcusDNA bindingFungicidal

Identifiers

PMID26209266
PMCPMC4554983
OpenAlexW2220059307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.